The authors of this study from 12 European Union member states used statistical modelling and a novel European approach for combining data to explore the potential causes that might explain difference in transmission dynamics observed during the early stages of the 2009 influenza A(H1N1) pandemic.
On 9 June, ECDC will be hosting a technical side-event to the United Nations High-Level Meeting on AIDS 2011. The event will highlight how countries and regions with differing epidemiology could improve their responses to HIV/AIDS.
In his speech before the EU Health Ministers recently, ECDC Director Marc Sprenger outlined several public health measures to meet the measles elimination target by 2015 in Luxembourg.
The European Medicines Agency (EMA) was key in the Europe during the 2009 pandemic concerning the authorisation and the benefit – risk assessment of the novel pandemic vaccines.
In late March, 2011 ECDC reported that the Swedish Medical Product Agency published preliminary results from an on-going cohort study involving 5.3 million people, where 67% of children and adolescents and 51.0% of adults were vaccinated with Pandemrix.
ECDC and WHO Europe jointly release “MESSAGE - MEaSles and rubella Self Assessment GEnerating tool” for public health experts, to facilitate assessment of the progress made towards measles and rubella elimination.
ECDC Director Marc Sprenger at the European Parliament Committee on the Environment, Public Health and Food Safety (ENVI) stressed the importance of the EU’s continuous commitment in the fight against hepatitis B and hepatitis C.
A double-blind, placebo-controlled, dose-escalation, phase 1 study was performed in 60 healthy subjects between 18 and 49 years of age. The two-dose regimen induced the development of neutralizing antibodies in high percentages of the subjects (from 88% to 100% of subjects depending on antigen content)”.